SJG-136 in Treating Patients With Advanced Solid Tumors

Inclusion Criteria

• •Histologically confirmed solid tumor
• •* Advanced disease, defined as metastatic or unresectable disease
• •Measurable indicator lesions
• •Standard curative or palliative measures do not exist or are no longer effective
• •Previously treated CNS metastases allowed provided patient has completed local therapy AND corticosteroids have been discontinued for at least 4 weeks
• •No known leptomeningeal metastases
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 60-100%
• •More than 3 months
• •WBC ≥ 3,000/mm\^3
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Bilirubin ≤ 1.0 mg/dL
• •AST and ALT ≤ 2.5 times upper limit of normal
• •Creatinine \< 1.4 mg/dL
• •No congestive heart failure
• •No recent myocardial infarction
• •No unstable angina
• •No uncontrolled hypertension
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No active infection
• •No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drug
• •No other significant medical history, unstable medical condition, or unstable systemic disease that would preclude study participation
• •At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas and 8 weeks for UCN-01)
• •At least 4 weeks since prior radiotherapy
• •No prior radiotherapy to ≥ 25% of hematopoietic bone marrow
• •Recovered from all prior therapy
• •At least 4 weeks since prior investigational anticancer drugs
• •No other concurrent investigational agents
• •No concurrent combination antiretroviral therapy for HIV-positive patients